AIM ImmunoTech Inc. Common Stock (AIM)
2.6389
+0.1589 (6.41%)
NYSE · Last Trade: Aug 21st, 3:23 PM EDT
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · July 29, 2025
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.
Via Chartmill · July 29, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · July 29, 2025
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via Chartmill · July 29, 2025
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · July 29, 2025
Via Benzinga · July 29, 2025
Via Benzinga · July 29, 2025
AIM ImmunoTech shares rise after DURIPANC trial data show superior survival and safety in metastatic pancreatic cancer patients.
Via Benzinga · July 28, 2025
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.
Via Chartmill · July 28, 2025
Via Benzinga · July 28, 2025
Via Benzinga · April 4, 2025
Via Benzinga · March 31, 2025

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.
Via Stocktwits · March 2, 2025

Via Benzinga · October 3, 2024